Enveda Raises $311M Series E to Advance AI-Powered Drug Discovery

Enveda Biosciences has raised $311 million in Series E funding as the nature-derived drug discovery company enters its next phase of development and seeks to advance multiple drug candidates through clinical trials.

The latest financing follows more than $500 million raised across the company's first four funding rounds and comes as Enveda prepares to move its pipeline toward later-stage development.

CEO Viswa Colluru, Ph.D., said the company's long-term ambition is to become a household name and develop medicines that could ultimately affect hundreds of millions of people.

The new capital is intended to help Enveda build a business capable of taking medicines from discovery through late-stage development, with artificial intelligence playing a central role in the company's approach to drug discovery and development.

The financing follows a series of clinical milestones for the biotech during 2026, including data from two drug candidates and the start of human testing for a third molecule.

From nature to new medicines

Enveda's drug discovery approach focuses on chemistry derived from nature.

The company searches organisms for novel chemical compounds that could potentially be developed into medicines.

Its technology platform combines this nature-derived chemistry with artificial intelligence in an effort to identify and develop drug candidates more efficiently.

The company's broader goal is not simply to discover molecules but to build an integrated pharmaceutical development platform capable of moving candidates from early discovery through clinical development.

That ambition is now being tested through several candidates already in human trials.

The company's latest financing gives it additional resources to advance those programs while continuing to develop other candidates from its broader pipeline.

ENV-294 advances in atopic dermatitis

One of Enveda's most advanced programs is ENV-294, an oral small molecule being developed for inflammatory diseases.

The company reported Phase 1b data for ENV-294 in July 2026.

According to the results cited in the source, the treatment was associated with a mean 68% reduction in eczema area and severity by Day 28.

The reduction reached 85% by Day 42.

Enveda is now running Phase 2a trials of ENV-294 in atopic dermatitis and asthma.

The program represents one of the first major tests of whether Enveda's drug discovery approach can translate into clinically meaningful outcomes.

The Series E financing is expected to support the progression of ENV-294 into later-stage development while allowing the company to explore additional indications.

ENV-308 aims to mimic exercise

Another major program is ENV-308, which is being developed around a different concept.

Enveda is attempting to create an oral medicine that can mimic some of the effects associated with exercise.

The candidate is designed to replicate the effects of N-lactoyl-phenylalanine, a hormone associated with the body's response after exercise.

The goal is to create a treatment suitable for daily oral dosing.

The company is specifically investigating whether ENV-308 could help people maintain weight loss after stopping GLP-1 medications.

Enveda reported Phase 1 results for ENV-308 in healthy volunteers in August 2026.

The program is still in an early stage, meaning additional clinical development will be required before its potential therapeutic effects can be established.

The Series E round will support the advancement of ENV-308 into later-stage trials and additional indications.

Third candidate enters clinical development

Enveda is also developing ENV-6946 as a potential treatment for inflammatory bowel disease.

The molecule is currently in Phase 1 development.

The latest funding will allow the company to advance ENV-6946 toward mid-stage clinical development while continuing to move its more advanced programs forward.

This creates a broader pipeline strategy rather than relying on a single drug candidate.

ENV-294, ENV-308, and ENV-6946 are at different stages of development and target different diseases or therapeutic areas.

Enveda expects the Series E financing to provide enough capital not only to advance these programs but also to move additional candidates from its pipeline into clinical testing.

AI as the foundation of the platform

Artificial intelligence sits at the centre of Enveda's strategy.

The company believes AI can help improve the speed and economics of drug discovery and development.

Traditional pharmaceutical development can take many years and require substantial investment before a candidate reaches patients.

Enveda's strategy is to use AI alongside its nature-derived chemistry platform to identify promising compounds and support their development.

The company wants to build a vertically integrated organisation capable of taking medicines from initial discovery through late-stage clinical development.

CEO Viswa Colluru has framed the company's ambition around changing the timelines and costs associated with pharmaceutical development.

The latest funding gives Enveda the resources to test that approach against increasingly advanced clinical programs.

A rapidly expanding funding history

The Series E round continues Enveda's rapid fundraising trajectory.

The company raised $130 million in Series C funding in November 2024.

It followed that with a $150 million Series D round in September 2025.

Across its first four funding rounds, Enveda had already raised more than $500 million before the latest financing.

The new $311 million Series E therefore brings another substantial pool of capital into the business at a point when multiple programs are already in human trials.

Rather than using the capital exclusively for early-stage discovery, Enveda can now direct funding toward clinical development and the infrastructure required to advance medicines toward later stages.

Building toward a larger pharmaceutical business

Enveda's latest funding marks a shift in the company's development.

Its early fundraising was focused heavily on building its drug discovery platform and generating a pipeline.

The company is now entering a phase in which clinical execution becomes increasingly important.

ENV-294 is already in Phase 2a trials for atopic dermatitis and asthma.

ENV-308 has completed its Phase 1 work in healthy volunteers and is moving toward further development.

ENV-6946 remains in Phase 1 for inflammatory bowel disease.

The company also expects to move additional candidates into clinical testing.

That means Enveda will need to demonstrate not only that its AI and nature-derived discovery platform can identify promising molecules, but also that those candidates can progress through increasingly demanding clinical development.

The next decade for Enveda

With $311 million in new capital, Enveda is positioning itself for a much larger clinical and commercial development effort.

The company's ambition is to develop medicines that could ultimately reach hundreds of millions of people.

The immediate focus, however, remains on its clinical pipeline.

ENV-294 will provide an important test of the company's approach in inflammatory disease, while ENV-308 could open another avenue around weight management and metabolic health if future trials support its intended effects.

ENV-6946 provides another opportunity in inflammatory bowel disease.

The company expects the Series E financing to fund later-stage trials for its lead programs, mid-stage development for ENV-6946, and additional candidates entering clinical testing.

Enveda's next phase will therefore be defined by clinical execution.

The company has already raised more than $800 million across its disclosed funding rounds when including the latest Series E. The next challenge is converting that capital, its AI platform, and its nature-derived drug discovery approach into medicines that can successfully progress through clinical development and ultimately reach patients.